Molecular biomarker set for early detection of ovarian cancer
AssigneeKing Abdullah University of Science and Technology
InventorsVladimir Bajic, Mandeep Kaur
Life of this patent
Estimating the term…
Abstract
Embodiments of the present invention concern methods and compositions related to detection of ovarian cancer, including detection of the stage of ovarian cancer, in some cases. In particular, the invention encompasses use of expression of TFAP2A and in some embodiments CA125 and/or E2F5 to identify ovarian cancer, including detecting mRNA and/or protein levels of the respective gene products. Kits for detection of ovarian cancer are also described.
Claims28
A method of identifying ovarian cancer in an individual or the risk of developing ovarian cancer in an individual, comprising the step of assaying for expression of TFAP2A in the individual.
A method of identifying ovarian cancer in an individual or the risk of developing ovarian cancer in an individual, comprising the step of comparing the expression level of TFAP2A from the individual with the expression level of TFAP2A from a control.
A method of identifying ovarian cancer in an individual or the risk of developing ovarian cancer in an individual, comprising the step of detecting expression of TFAP2A in an individual, wherein expression of TFAP2A indicates the presence of ovarian cancer or the risk of developing ovarian cancer in the individual.
A method of identifying ovarian cancer in an individual or the risk of developing ovarian cancer in an individual, comprising the steps:
- a) comparing the expression level of TFAP2A from the individual with the expression level of TFAP2A from a control, and
- b) comparing the expression level of CA125 or E2F5 from the individual with the expression level of CA125 or E2F5 from a control.
A method of identifying ovarian cancer in an individual or the risk of developing ovarian cancer in an individual, comprising the step of comparing the expression level of TFAP2A, CA125 and E2F5 from the individual and the expression level of TFAP2A, CA125 and E2F5 from a control.
A kit comprising one or more detection reagents for TFAP2A and optionally one or more detection reagents for one or both of CA125 and E2F5, said reagents housed in a suitable container.
A method of identifying ovarian cancer in an individual or the risk of developing ovarian cancer in an individual, comprising the steps of
- a) obtaining a sample from the individual,
- b) determining the expression level of TFAP2A from the sample, and
- c) comparing the expression level of TFAP2A from the individual with the expression level of TFAP2A from a control.
A method of identifying ovarian cancer in an individual or the risk of developing ovarian cancer in an individual, comprising the steps of
- a) obtaining a sample from the individual,
- b) determining the expression level of TFAP2A from the sample,
- c) determining the expression level of CA125 and/or E2F5 from the sample,
- d) comparing the expression level of TFAP2A from the individual with the expression level of TFAP2A from a control, and
- e) comparing the expression level of CA125 and/or E2F5 from the individual with the expression level of CA125 and/or E2F5 from a control.
Dependencies are inferred from the claim text.